Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink.

In this episode, Fierce Biotech’s Darren Incorvaia and Gabrielle Masson came together to chat about themes from this year’s graveyard, including a cell therapy mausoleum, some mad science, and Darren’s incredibly dated reference to a novelty song from 1958. 

To learn more about the topics in this episode: 
The 2025 Biotech Graveyard

Welcome to the Fierce Biotech Graveyard, our annual ritual remembering the biotechs we lost in 2025 and those on the brink.
In this episode, Fierce Biotech&rsquo;s Darren Incorvaia and Gabrielle Masson came together to chat about themes from this year&rsquo;s graveyard, including a cell therapy mausoleum, some mad science, and Darren&rsquo;s incredibly dated reference to a novelty song from 1958.&nbsp;
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercebiotech.com/special-reports/2025-biotech-graveyard">The 2025 Biotech Graveyard</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Biotech Graveyard

As payers focus on long-term outcomes and real-world performance, value matters more than ever. RTI Health Solutions experts discuss how clear evidence storytelling drives access decisions.

As payers focus on long-term outcomes and real-world performance, value matters more than ever. RTI Health Solutions experts discuss how clear evidence storytelling drives access decisions.

From approval to value: Why evidence storytelling now matters (Sponsored)

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in reviewing new drug applications.

By the end of the year, the approval picture told a more complicated story, with momentum building after a slow start.

This week on "The Top Line," we dig into what the numbers really show, which companies and therapies came out on top, and what the FDA’s performance over the course of 2025 signals for the drug review process going forward.

To learn more about the topics in this episode: 
2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products
2024 drug approvals: Small companies loom large with several key FDA nods
2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer

In early 2025, the FDA was rocked by sweeping layoffs and leadership turnover, raising questions about whether the agency could maintain its pace in reviewing new drug applications.
By the end of the year, the approval picture told a more complicated story, with momentum building after a slow start.
This week on "The Top Line," we dig into what the numbers really show, which companies and therapies came out on top, and what the FDA&rsquo;s performance over the course of 2025 signals for the drug review process going forward.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/2025-drug-approvals">2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products</a></li>
<li><a href="https://www.fiercepharma.com/pharma/2024-drug-approvals">2024 drug approvals: Small companies loom large with several key FDA nods</a></li>
<li><a href="https://www.fiercepharma.com/special-reports/2023-drug-approvals-after-down-year-fda-signs-bounty-new-medicines">2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer</a></li>
</ul>

Drug approvals went from crawl to sprint in 2025

What does it really mean to put patients first in today’s life sciences landscape? In this sponsored episode of The Top Line, leaders from RTI Health Solutions explore how patient voices are transforming evidence generation, market access and medical communication. From patient-reported outcomes and advisory boards to inclusive value storytelling and trust-building across diverse communities, the discussion highlights why patient-centric strategies are no longer optional—and how they can influence approval, reimbursement and real-world impact.

What does it really mean to put patients first in today&rsquo;s life sciences landscape? In this sponsored episode of The Top Line, leaders from RTI Health Solutions explore how patient voices are transforming evidence generation, market access and medical communication. From patient-reported outcomes and advisory boards to inclusive value storytelling and trust-building across diverse communities, the discussion highlights why patient-centric strategies are no longer optional&mdash;and how they can influence approval, reimbursement and real-world impact.

RTI Health Solutions leaders explain how patient voices are reshaping evidence generation, access and value communication

Biotech Graveyard

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips